Kaji Kosuke 鍛治孝祐

Researcher Number	20623490
Other IDs
Affiliation (Current)	2025: 奈良県立医科大学, 医学部, 講師
Affiliation (based on the past Project Information) *help	2021 – 2024: 奈良県立医科大学, 医学部, 講師 2017 – 2019: 奈良県立医科大学, 医学部, 学内講師 2016 – 2017: 奈良県立医科大学, 医学部, 助教
Review Section/Research Field	Principal Investigator Gastroenterology Except Principal Investigator Basic Section 53010:Gastroenterology-related / Basic Section 57080:Social dentistry-related / Gastroenterology
Keywords	Principal Investigator 細胞老化 / DNAメチル化 / 肝星細胞 / 肝線維化 / DNMT1 Except Principal Investigator エンドトキシン / 肝硬変 / 肝臓学 / ヒアルロン酸ミセル / 肝線維化 … More / サルコペニア / バイオマーカー / 急性腎障害 / ACLF / 急性肝不全 / VWF / ADAMTS13 / 非アルコール性脂肪肝炎 / 内毒素 / 残歯数 / 口腔状態 / 歯周病 / Gut-Liver axis / 肝星細胞 / ARB / Leaky Gut / アンジオテンシン受容体阻害薬 / 新規マーカー / 肝癌 / 腸内細菌 Less

A new strategy for the treatment of cirrhotic sarcopenia using a combination of exercise therapy and ADAMTS13 replacement therapy.
- Principal Investigator
  
  浪崎正
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Nara Medical University
Development of Simultaneous Control Therapy for Complications of Cirrhosis Using Enhanced Drug Repositioning
- Principal Investigator
  
  吉治仁志
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Nara Medical University
血液凝固制御因子ADAMTS13による急性肝不全新規治療法とバイオマーカーの開発
- Principal Investigator
  
  高谷広章
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Nara Medical University
Novel Liver Cirrhosis Treatment by Drug Repositioning and Leaky Gut Control
- Principal Investigator
  
  Yoshiji Hitoshi
- Project Period (FY)
  2021 – 2023
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Nara Medical University
歯周病と慢性肝疾患病態の関連解明－新たな肝疾患進展予防施策の探索
- Principal Investigator
  
  赤羽たけみ
- Project Period (FY)
  2021 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 57080:Social dentistry-related
- Research Institution
  Nara Medical University
Development of therapeutic method to suppress liver disease progression by drug repositioning
- Principal Investigator
  
  Yoshiji Hitoshi
- Project Period (FY)
  2017 – 2019
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Gastroenterology
- Research Institution
  Nara Medical University
Epigenetic approach to antifibrotic treatment for liver fibrosisPrincipal Investigator
- Principal Investigator
  
  Kaji Kosuke
- Project Period (FY)
  2016 – 2018
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Gastroenterology
- Research Institution
  Nara Medical University

All 2024 2023 2022 2021 2020 2019 2018 2017

All Journal Article Presentation

[Journal Article] Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats2024
- Author(s)
  Asada Shohei、Kaji Kosuke、Nishimura Norihisa、Koizumi Aritoshi、Matsuda Takuya、Tanaka Misako、Yorioka Nobuyuki、Sato Shinya、Kitagawa Koh、Namisaki Tadashi、Akahane Takemi、Yoshiji Hitoshi
- Journal Title
  
  Cells
  
  Volume: 13 Issue: 6 Pages: 538-538
- DOI
  10.3390/cells13060538
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitis2024
- Author(s)
  Tanaka Misako、Kaji Kosuke、Nishimura Norihisa、Asada Shohei、Koizumi Aritoshi、Matsuda Takuya、Yorioka Nobuyuki、Tsuji Yuki、Fujinaga Yukihisa、Sato Shinya、Namisaki Tadashi、Akahane Takemi、Yoshiji Hitoshi
- Journal Title
  
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  
  Volume: 1871 Issue: 2 Pages: 119649-119649
- DOI
  10.1016/j.bbamcr.2023.119649
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis2024
- Author(s)
  Asada Shohei、Namisaki Tadashi、Kaji Kosuke、Takaya Hiroaki、et al
- Journal Title
  
  Digestive Diseases and Sciences
  
  Volume: 69 Issue: 3 Pages: 851-869
- DOI
  10.1007/s10620-023-08257-w
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22K08084
[Journal Article] The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure2023
- Author(s)
  Takaya Hiroaki、Namisaki Tadashi、Enomoto Masahide、Kubo Takahiro、Tsuji Yuki、Fujinaga Yukihisa、Nishimura Norihisa、Kaji Kosuke、Kawaratani Hideto、Moriya Kei、Akahane Takemi、Matsumoto Masanori、Yoshiji Hitoshi
- Journal Title
  
  Biology
  
  Volume: 12 Issue: 2 Pages: 164-164
- DOI
  10.3390/biology12020164
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K08084
[Journal Article] A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation2023
- Author(s)
  Suzuki Junya、Kaji Kosuke、Nishimura Norihisa、Kubo Takahiro、Tomooka Fumimasa、Shibamoto Akihiko、Iwai Satoshi、Tsuji Yuki、Fujinaga Yukihisa、Kitagawa Koh、Namisaki Tadashi、Akahane Takemi、Yoshiji Hitoshi
- Journal Title
  
  Biomedicines
  
  Volume: 11 Issue: 5 Pages: 1295-1295
- DOI
  10.3390/biomedicines11051295
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib.2022
- Author(s)
  Fujimoto Y, Namisaki T, Takeda S, Murata K, Enomoto M, Takaya H, Tsuji Y, Fujinaga Y, Sawada Y, Nishimura N, Kitagawa K, Kaji K, Inoue T, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H.
- Journal Title
  
  Anticancer Res
  
  Volume: 42 Issue: 10 Pages: 4895-4905
- DOI
  10.21873/anticanres.15995
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.2022
- Author(s)
  Namisaki T, Kaji K, Shimozato N, Kaya D, Ozutsumi T, Tsuji Y, Fujinaga Y, Kitagawa K, Furukawa M, Sato S, Sawada Y, Nishimura N, Takaya H, Okura Y, Seki K, Kawaratani H, Moriya K, Noguchi R, Asada K, Akahane T, Mitoro A, Yoshiji H
- Journal Title
  
  Indian J Gastroenterol.
  
  Volume: 41 Issue: 2 Pages: 169-180
- DOI
  10.1007/s12664-021-01220-5
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis.2022
- Author(s)
  Enomoto M, Kaji K, Nishimura N, Fujimoto Y, Murata K, Takeda S, Tsuji Y, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Akahane T, Yoshiji H.
- Journal Title
  
  Dig Liver Dis
  
  Volume: 54 Issue: 10 Pages: 1392-1402
- DOI
  10.1016/j.dld.2022.04.012
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Rifaximin enhances the L carnitine mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut liver muscle axis.2022
- Author(s)
  Murata K, Kaji K, Nishimura N, Enomoto M, Fujimoto Y, Takeda S, Tsuji Y, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Akahane T, Yoshiji H
- Journal Title
  
  Int J Mol Med.
  
  Volume: 50 Issue: 2 Pages: 101-101
- DOI
  10.3892/ijmm.2022.5157
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity2021
- Author(s)
  Fujimoto Y, Kaji K, Nishimura N, Enomoto M, Murata K, Takeda S, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H.
- Journal Title
  
  World J Gastroenterol.
  
  Volume: 28 Issue: 48 Pages: 8323-8342
- DOI
  10.3748/wjg.v27.i48.8323
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nrf2-mediated antioxidant response and acetaldehyde metabolization with inhibition of the LPS/TLR4 signaling pathway2021
- Author(s)
  Ishida K, Kaji K, Sato S, Ogawa H, Takagi H, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H
- Journal Title
  
  J Nutr Biochem
  
  Volume: 89 Pages: 108573-108573
- DOI
  10.1016/j.jnutbio.2020.108573
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats2021
- Author(s)
  Takeda S, Kaji K, Nishimura N, Enomoto M, Fujimoto Y, Murata K, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji　H
- Journal Title
  
  Mol Nutr Food Res
  
  Volume: 65 Issue: 24
- DOI
  10.1002/mnfr.202100526
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients.2020
- Author(s)
  Kaji K, Saikawa S, Takaya H, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Tsuji Y, Sawada Y, Kawaratani H, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.
- Journal Title
  
  Antibiotics (Basel)
  
  Volume: 9 Issue: 4 Pages: 145-145
- DOI
  10.3390/antibiotics9040145
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K09438
[Journal Article] Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis.2020
- Author(s)
  Furukawa M, Moriya K, Nakayama J, Inoue T, Momoda R, Kawaratani H, Namisaki T, Sato S, Douhara A, Kaji K, Kitade M, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Tanaka Y, Yoshiji H.
- Journal Title
  
  Hepatol Res.
  
  Volume: 4 Issue: 7 Pages: 840-852
- DOI
  10.1111/hepr.13509
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K09438
[Journal Article] TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats2019
- Author(s)
  Kaya Daisuke、Kaji Kosuke、Tsuji Yuki、Yamashita Satoko、Kitagawa Koh、Ozutsumi Takahiro、Fujinaga Yukihisa、Takaya Hiroaki、Kawaratani Hideto、Moriya Kei、Namisaki Tadashi、Akahane Takemi、Yoshiji Hitoshi
- Journal Title
  
  Cells
  
  Volume: 8 Issue: 10 Pages: 1153-1153
- DOI
  10.3390/cells8101153
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-18K15824, KAKENHI-PROJECT-17K09438
[Journal Article] Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study.2019
- Author(s)
  Nakanishi K, Namisaki T, Mashitani T, Kaji K, Ozaki K, Saikawa S, Sato S, Inoue T, Sawada Y, Kitagawa K, Takaya H, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H.
- Journal Title
  
  Nutrients.
  
  Volume: 7 Issue: 9 Pages: 2140-2140
- DOI
  10.3390/nu11092140
- Data Source
  KAKENHI-PROJECT-17K09438
[Journal Article] Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.2019
- Author(s)
  Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, Kaji K, Shimozato N, Mashitani T, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yamao J, Yoshiji H.
- Journal Title
  
  Hepatol Res.
  
  Volume: 49 Issue: 3 Pages: 404-418
- DOI
  10.1111/hepr.13281
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K09438
[Journal Article] Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.2018
- Author(s)
  Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H.
- Journal Title
  
  International Journal of Cancer
  
  Volume: 142 Issue: 8 Pages: 17121722-17121722
- DOI
  10.1002/ijc.31193
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K09438
[Journal Article] Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model2018
- Author(s)
  Seki K, Kitade M, Nishimura N, Kaji K, Asada K, Namisaki T, Moriya K, Kawaratani H, Okura Y, Takaya H, Sawada Y, Sato S, Nakanishi K, Yoshiji H.
- Journal Title
  
  Oncotarget.
  
  Volume: 9 Issue: 47 Pages: 28638-51
- DOI
  10.18632/oncotarget.25587
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K09438
[Journal Article] von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.2018
- Author(s)
  Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H
- Journal Title
  
  United European Gastroenterol J.
  
  Volume: 6 Issue: 9 Pages: 1401-1409
- DOI
  10.1177/2050640618779660
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K09438, KAKENHI-PROJECT-16K10580
[Journal Article] Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats.2018
- Author(s)
  Nishimura N, Kaji K, Kitade M, Aihara Y, Sato S, Seki K, Sawada Y, Takaya H, Okura Y, Kawaratani H, Moriya K, Namisaki T, Mitoro A, Yoshiji H
- Journal Title
  
  BMC Cancer.
  
  Volume: 18 Issue: 1 Pages: 164-171
- DOI
  10.1186/s12885-018-5099-6
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K09438
[Journal Article] Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.2018
- Author(s)
  Saikawa S, Kaji K, Nishimura N, Seki K, Sato S, Nakanishi K, Kitagawa K, Kawaratani H, Kitade M, Moriya K, Namisaki T, Mitoro A, Yoshiji H.
- Journal Title
  
  Cancer Letters
  
  Volume: 434 Pages: 120-129
- DOI
  10.1016/j.canlet.2018.07.021
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K09438
[Journal Article] Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.2017
- Author(s)
  Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.
- Journal Title
  
  World J Gastroenterol.
  
  Volume: 23 Issue: 47 Pages: 83358366-83358366
- DOI
  10.3748/wjg.v23.i47.8355
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K09438
[Journal Article] Effect of combined farnesoid X receptor agonist and angiotensin Ⅱtipe 1 receptor blocker on hepatic fibrosis.2017
- Author(s)
  Namisaki T. Moriya K, Kitade M, Takeda K, Kaji K, Okura Y, Shimozato N. Sato S, Nishimura N, Seki K, Kawaratani H, Takaya H, Sawada Y, Akahane T, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Noguchi R, Asada K, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya H Yoshiji
- Journal Title
  
  Hepatol commun.
  
  Volume: 1 Issue: 9 Pages: 928945-928945
- DOI
  10.1002/hep4.1104
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K09438, KAKENHI-PROJECT-15K08077
[Presentation] Dual Angiotensin II Receptor and Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation2023
- Author(s)
  Suzuki J, Kaji K, Nishimura N, Kubo T, Tomooka F, Shibamoto A, Iwai S, Tsuji Y, Fujinaga Y, Kitagawa K, Namisaki T, Akahane T, Yoshiji H
- Organizer
  APASL
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] Vitamin D Deficiency Exacerbates Alcohol-related Liver Injury via Gut Barrier Disruptionand Hepatic Overload of Endotoxin2023
- Author(s)
  Shibamoto A, Kaji K, Yoshiji H
- Organizer
  APASL
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] Glucagon-like Peptide-1 Receptor Agonist, Semaglutide Attenuates Chronic Liver Disease-induced Skeletal Muscle Atrophy in Diabetic Mice2023
- Author(s)
  Iwai S, Kaji K, Nishimura N, Kubo T, Tomooka F, Shibamoto A, Suzuki J, Tsuji Y, Fujinaga Y, Kitagawa K, Namisaki T, Akahane T, Yoshiji H
- Organizer
  APASL
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] ARB potentiate the Protective Effect of BCAA on Skeletal Muscle Atrophy in Cirrhotic Rats2022
- Author(s)
  Takeda S, Kaji K, Yoshiji H
- Organizer
  日本肝臓学会大会　JDDW2022
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] 肝硬変ラット骨格筋委縮に対するRifaximin/L/carnitine 併用療法の効果2022
- Author(s)
  村田晃児、鍛治孝祐、吉治仁志
- Organizer
  日本肝臓学会総会
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] Lubiprosone と Rifaximin 併用による gut-liver axis 制御とNASH肝繊維化抑制効果2022
- Author(s)
  榎本壮秀、鍛治孝祐、吉治仁志
- Organizer
  日本肝臓学会総会
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] Rifaximin および L-carnitine併用による肝硬変ラット骨格筋委縮に対する予防効果の検討2022
- Author(s)
  村田晃児、鍛治孝祐、吉治仁志
- Organizer
  日本門脈圧亢進症学会総会
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] Rifaximin/L-carnitine 併用による肝硬変ラット骨格筋委縮に対する予防効果2022
- Author(s)
  村田晃児、鍛治孝祐、高谷広章、瓦谷英人、守屋圭、浪崎正、赤羽たけみ、美登路昭、吉治仁志
- Organizer
  日本消化器病学会総会
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] LPSにより肝星細胞から産生される epiregulin の肝癌進展における役割とその作用機序2022
- Author(s)
  久保貴裕、鍛治孝祐、吉治仁志
- Organizer
  日本消化器病学会総会
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] アルコール性肝障害モデルマウスを用いた、酢酸亜鉛とリファキシミン併用療法による肝繊維化予防効果の検討2022
- Author(s)
  藤本優樹、鍛治孝祐、吉治仁志
- Organizer
  日本肝臓学会総会
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] ACLFにおけるADAMTS13の動態2022
- Author(s)
  高谷広章, 浪崎正, 鍛治孝祐, 西村典久, 吉治仁志
- Organizer
  第48回日本急性肝不全研究会
- Data Source
  KAKENHI-PROJECT-22K08084
[Presentation] アルコール肝障害モデルマウスを用いた酢酸亜鉛とリファキシミン併用療法による肝繊維化予防効果の検討2022
- Author(s)
  藤本優樹、鍛治孝祐、、吉治仁志
- Organizer
  日本消化器病学会総会
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] Exogenous administration of low-dose lipopolysaccharide potentiates the development of liver fibrosis in a choline-deficient L-amino-acide-defined diet-induced murine steatohepatitis model2019
- Author(s)
  Nakanishi K, Kaya D, Tsuji Y, Saikawa S, Kaji K, Akahane T, Namisaki T, Yoshiji H
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438
[Presentation] Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity2019
- Author(s)
  Takaya H, Kaji K, Saikawa S, Furukawa M, Sato S, Sawada Y, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H
- Organizer
  EASL
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438
[Presentation] Combined treatment with anti-diabetic agents:dipeptidyl peptidase-4 inhibitor(DPP4-1) and sodiumglucose co-transporter-2 inhibitor(SGLT2-1) suppresses progression in nash rat model2019
- Author(s)
  Namisaki T, Ozutsumi T, Kaji K, Shimozato N, Saikawa S, Takaya　H,　Nakanishi　K,　Tsuji　Y,　Sawada　Y,　Furukawa　M,　Fujinaga　Y,　Kaya　D,　Kawaratani　H, Akahane T, Yoshiji H
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438
[Presentation] Effect of ARB and Rifaximin combination therapy on hepatic fibrosis in nonalcoholic steatohepatitis model rats2019
- Author(s)
  Fujinaga Y, Kawaratani H, Namisaki T, Moriya K, kaji K, Takaya H, Sawada Y, Akahane T, Sato S, Shimozato N, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Yoshiji H
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438
[Presentation] The potential effect of combination therapies with a farnesoid　X receptor(FXR)agonist on hepatic fibrogenesis in rat nash model2019
- Author(s)
  Shimozato N, Namisaki T, Kaji K, Takaya H, Saikawa S, Sawada Y, Nakanishi K, Furukawa M, Fujinaga Y, Kaya D, Tsuji Y, Kawaratani H, Akahane T, Yoshiji H
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438
[Presentation] Rifaximin alleviates endotoxemia with improvement of intestinal hyperpermeability and minor changes in fecal microbiota in cirrohotic patients with hepatic encephalopathy2018
- Author(s)
  Kaji K, Saikawa S, Takaya H, Sato S, Kitade M, Moriya K, Namisaki T, Akahane T, Yoshiji H
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438
[Presentation] Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity2018
- Author(s)
  Takaya H, Kaji K, Saikawa S, Furukawa M, Sato S, Sawada Y, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H
- Organizer
  EASL
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438
[Presentation] Ratio of Von Willebrand Factor to ADAMTS13 is a Novel Potential Biomarker for Early Diagnosis of HCC2018
- Author(s)
  Takaya H, Namisaki T, Kitade M, Kaji K, Shimozato N, Akahane T, Moriya K, Kawaratani H, Sawada Y, Seki K, Sato S, Nakanishi K, Yoshiji H
- Organizer
  APASL
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438
[Presentation] Moderate alcohol consumption protects against fatty liver in males2018
- Author(s)
  Akahane T, Namisaki T, Kitade M, Kaji K, Takaya H, Shimozato N, Sato S, Yoshiji H
- Organizer
  EASL
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438
[Presentation] Identification of von willebrand factor-to-ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma in patients with liver cirrhosis2018
- Author(s)
  Takaya H, Namisaki T, Kaji K, Kitade M, Tsuji Y, Fujinaga Y, Furukawa M, Nakanishi K, Seki K, Sato S, Sawada Y, Saikawa S, Shimozato N, Kawaratani H, Asada K, Moriya K, Akahane T, Yoshiji H
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438
[Presentation] Beneficial effects of combined farnesoid X receptor agonist(INT747) and dipeptidyl peptidase-4 inhibitor(sitagliptin) on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis2017
- Author(s)
  Shimozato N, Namisaki T, Moriya K, Kitade M, Takeda K, Kawaratani H, Kaji K, Okura Y, Takaya H, Sawada Y, Nishimura N, Sato S, Saikawa S, Seki K, Furukawa M, Nakanishi K, Kubo T, Yoshiji H
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438
[Presentation] ADAMTS13 deficiency exacerbates acute liver failure with enhanced VWF accumulation and hepatic inflammation in mice.2017
- Author(s)
  Takaya H, Kaji K, Kitade M, Seki K, Saikawa S, Nishimura N, Sato S, Sawada Y, Okura Y, Kawaratani H, Akahane T, Moriya K, Namisaki T, Mitoro A, Yoshiji H
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09438

1. Yoshiji Hitoshi (40336855)

# of Collaborated Projects: 6 results

# of Collaborated Products: 46 results
2. 浪崎正 (20526850)

# of Collaborated Projects: 4 results

# of Collaborated Products: 16 results
3. 高谷広章 (40745460)

# of Collaborated Projects: 2 results

# of Collaborated Products: 3 results
4. 北出光輝 (40526795)

# of Collaborated Projects: 1 results

# of Collaborated Products: 17 results
5. 赤羽たけみ (70423910)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
6. 仲川洋介 (00714875)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. 赤羽学 (40326327)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. 井上隆 (00783044)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
9. 芝本彰彦 (20896724)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
10. 佐藤慎哉 (80790352)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
11. 賀屋大介

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Kaji Kosuke 鍛治 孝祐

Research Projects

Research Products

Co-Researchers

A new strategy for the treatment of cirrhotic sarcopenia using a combination of exercise therapy and ADAMTS13 replacement therapy.

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of Simultaneous Control Therapy for Complications of Cirrhosis Using Enhanced Drug Repositioning

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

血液凝固制御因子ADAMTS13による急性肝不全新規治療法とバイオマーカーの開発

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Novel Liver Cirrhosis Treatment by Drug Repositioning and Leaky Gut Control

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

歯周病と慢性肝疾患病態の関連解明－新たな肝疾患進展予防施策の探索

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of therapeutic method to suppress liver disease progression by drug repositioning

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Epigenetic approach to antifibrotic treatment for liver fibrosisPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitis2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib.2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.2022

Author(s)

Journal Title

DOI

Kaji Kosuke 鍛治孝祐